CHICAGO--(BUSINESS WIRE)--#GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 8:00am Eastern Time.
A live webcast of the event will be available on the 'Events & Presentations' section of Xeris' Investor Relations website at . A replay of the webcast will be available for 30 days.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev, for the treatment of endogenous Cushing's syndrome; Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs to bring new products forward using its proprietary formulation technology platforms, XeriSol and XeriJect, supporting long-term product development and commercial success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit , or follow us on X, LinkedIn, or Instagram.
Contacts
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
